Randomized trial: No benefit from corticosteroid nasal spray for recovery of smell sensation in COVID-19 patients
Corticosteroid nasal spray for recovery of smell sensation in COVID-19 patients: A randomized controlled trial – American Journal of Otolaryngology
The post Randomized trial: No benefit from corticosteroid nasal spray for recovery of smell sensation in COVID-19 patients appeared first on Links Medicus.
CDC Report: Allergic reactions including anaphylaxis after receipt of the first dose of Moderna COVID-19 vaccine
Allergic Reactions Including Anaphylaxis After Receipt of the First Dose of Moderna COVID-19 Vaccine — United States, December 21, 2020–January 10, 2021 – CDC Morbidity and Mortality Weekly Report Commentary: CDC reports rare allergic reactions to Moderna’s Covid-19 vaccine – STAT
The post CDC Report: Allergic reactions including anaphylaxis after receipt of the first dose of Moderna COVID-19 vaccine appeared first on Links Medicus.
Systematic review: At least one third of SARS-CoV-2 infections are asymptomatic
The Proportion of SARS-CoV-2 Infections That Are Asymptomatic: A Systematic Review – Annals of Internal Medicine Commentary from the authors: The day we let Covid-19 spin out of control – STAT
The post Systematic review: At least one third of SARS-CoV-2 infections are asymptomatic appeared first on Links Medicus.
Managing the long term effects of covid-19: summary of NICE, SIGN, and RCGP rapid guideline
Managing the long term effects of covid-19: summary of NICE, SIGN, and RCGP rapid guideline – The BMJ Original Guideline: COVID-19 rapid guideline: managing the long-term effects of COVID-19 – National Institute for Health and Care Excellence
The post Managing the long term effects of covid-19: summary of NICE, SIGN, and RCGP rapid guideline appeared first on Links Medicus.
Randomized trial: Bamlanivimab associated with Etesevimab reduce the viral load in patients with mild to moderate COVID-19
Effect of Bamlanivimab as Monotherapy or in Combination With Etesevimab on Viral Load in Patients With Mild to Moderate COVID-19: A Randomized Clinical Trial – JAMA Editorial: Neutralizing Monoclonal Antibody for Mild to Moderate COVID-19
The post Randomized trial: Bamlanivimab associated with Etesevimab reduce the viral load in patients with mild to moderate COVID-19 appeared first on Links Medicus.
Randomized trial: Anakinra (IL-1 receptor antagonist) does not improve outcomes in patients with mild-to-moderate COVID-19
Effect of anakinra versus usual care in adults in hospital with COVID-19 and mild-to-moderate pneumonia (CORIMUNO-ANA-1): a randomised controlled trial – The Lancet Respiratory Medicine Commentary: The right place for IL-1 inhibition in COVID-19 – The Lancet Respiratory Medicine Commentary on Twitter NEW Research—Anakinra did not improve outcomes in patients with mild-to-moderate #COVID19 pneumonia […]
The post Randomized trial: Anakinra (IL-1 receptor antagonist) does not improve outcomes in patients with mild-to-moderate COVID-19 appeared first on Links Medicus.
[Press Release – Not Published Yet] Full-dose blood thinners decreased need for life support and improved outcome in hospitalized COVID-19 patients
Full-dose blood thinners decreased need for life support and improved outcome in hospitalized COVID-19 patients – National Institutes of Health
The post [Press Release – Not Published Yet] Full-dose blood thinners decreased need for life support and improved outcome in hospitalized COVID-19 patients appeared first on Links Medicus.
[Press Release – Not Published Yet] Colchicine reduces the risk of COVID-19-related complications: Positive results from COLCORONA trial show that colchicine is the only effective oral medication for treating non-hospitalized patients
Colchicine reduces the risk of COVID-19-related complications: Positive results from COLCORONA trial show that colchicine is the only effective oral medication for treating non-hospitalized patients – Montreal Heart Insititute Study Protocol: Colchicine Coronavirus SARS-CoV2 Trial (COLCORONA) (COVID-19) – ClinicalTrials.gov “Patients will receive study medication colchicine 0.5 mg per os (PO) twice daily for the first […]
The post [Press Release – Not Published Yet] Colchicine reduces the risk of COVID-19-related complications: Positive results from COLCORONA trial show that colchicine is the only effective oral medication for treating non-hospitalized patients appeared first on Links Medicus.
Randomized trial: Benralizumab effects on health-related quality of life, exacerbation rate, lung function, and nasal polyposis symptoms for patients with severe eosinophilic asthma
Onset of effect and impact on health-related quality of life, exacerbation rate, lung function, and nasal polyposis symptoms for patients with severe eosinophilic asthma treated with benralizumab (ANDHI): a randomised, controlled, phase 3b trial – The Lancet Respiratory Medicine (link to abstract – $ for full-text) Commentary on Twitter NEW Research—#Benralizumab significantly reduced exacerbation […]
The post Randomized trial: Benralizumab effects on health-related quality of life, exacerbation rate, lung function, and nasal polyposis symptoms for patients with severe eosinophilic asthma appeared first on Links Medicus.
Twenty articles that critical care clinicians should read about COVID-19
Twenty articles that critical care clinicians should read about COVID-19 – Intensive Care Medicine Commentary on Twitter Main early papers on #COVID19 & their findings, an overview:➡️ manifestations of severe disease➡️ pharmacological therapy➡️ ventilatory support in pts with #SARSCoV2 related #ARDS➡️ healthcare organization & healthcare worker stress#FOAMcc #COVIDFOAM https://t.co/PvwsKhHn9v pic.twitter.com/QVg4zXU5TT — Intens Care Med […]
The post Twenty articles that critical care clinicians should read about COVID-19 appeared first on Links Medicus.